1068 related articles for article (PubMed ID: 33059196)
1. Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context.
Wiesweg M; Mairinger F; Reis H; Goetz M; Kollmeier J; Misch D; Stephan-Falkenau S; Mairinger T; Walter RFH; Hager T; Metzenmacher M; Eberhardt WEE; Zaun G; Köster J; Stuschke M; Aigner C; Darwiche K; Schmid KW; Rahmann S; Schuler M
Eur J Cancer; 2020 Nov; 140():76-85. PubMed ID: 33059196
[TBL] [Abstract][Full Text] [Related]
2. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
Front Immunol; 2021; 12():646874. PubMed ID: 33927719
[TBL] [Abstract][Full Text] [Related]
3. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
4. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
5. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
[TBL] [Abstract][Full Text] [Related]
7. A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.
Takada K; Toyokawa G; Okamoto T; Shimokawa M; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
Clin Lung Cancer; 2017 Sep; 18(5):572-582.e1. PubMed ID: 28318951
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ
Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346
[TBL] [Abstract][Full Text] [Related]
9. Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab.
Vennapusa B; Baker B; Kowanetz M; Boone J; Menzl I; Bruey JM; Fine G; Mariathasan S; McCaffery I; Mocci S; Rost S; Smith D; Dennis E; Tang SY; Damadzadeh B; Walker E; Hegde PS; Williams JA; Koeppen H; Boyd Z
Appl Immunohistochem Mol Morphol; 2019 Feb; 27(2):92-100. PubMed ID: 29346180
[TBL] [Abstract][Full Text] [Related]
10. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
[TBL] [Abstract][Full Text] [Related]
11. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
12. Programmed death-ligand 1 expression on direct Pap-stained cytology smears from non-small cell lung cancer: Comparison with cell blocks and surgical resection specimens.
Lozano MD; Abengozar-Muela M; Echeveste JI; Subtil JC; Bertó J; Gúrpide A; Calvo A; de Andrea CE
Cancer Cytopathol; 2019 Jul; 127(7):470-480. PubMed ID: 31245924
[TBL] [Abstract][Full Text] [Related]
13. Programmed cell death ligand 1 expression in cytologic and surgical non-small cell lung carcinoma specimens from a single institution: Association with clinicopathologic features and molecular alterations.
Mei P; Shilo K; Wei L; Shen R; Tonkovich D; Li Z
Cancer Cytopathol; 2019 Jul; 127(7):447-457. PubMed ID: 31025831
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.
Soo RA; Lim SM; Syn NL; Teng R; Soong R; Mok TSK; Cho BC
Lung Cancer; 2018 Jan; 115():12-20. PubMed ID: 29290252
[TBL] [Abstract][Full Text] [Related]
15. Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies.
Sui H; Ma N; Wang Y; Li H; Liu X; Su Y; Yang J
J Immunol Res; 2018; 2018():6984948. PubMed ID: 30159341
[TBL] [Abstract][Full Text] [Related]
16. Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing.
Kim HS; Cha H; Kim J; Park WY; Choi YL; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Eur J Cancer; 2019 Oct; 120():65-74. PubMed ID: 31493723
[TBL] [Abstract][Full Text] [Related]
17. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
[TBL] [Abstract][Full Text] [Related]
18. The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer.
Zhang S; Bai X; Shan F
Int Immunopharmacol; 2020 Mar; 80():106247. PubMed ID: 32007710
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.
Masuda K; Horinouchi H; Tanaka M; Higashiyama R; Shinno Y; Sato J; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Yamamoto N; Ohe Y
J Cancer Res Clin Oncol; 2021 Jan; 147(1):245-251. PubMed ID: 32705363
[TBL] [Abstract][Full Text] [Related]
20. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
